Market News on China Diagnostic Reagent Industry, 2015 report available at ResearchMoz

Posted by David Lee at 02:14 on Monday 8 June 2015
ALBANY, NY, JUNE 2015 -- ResearchMoz.us includes new market research report " China Diagnostic Reagent Industry, 2015: Global Market Size, Shares, Growth, Analysis, Summary, Trends and Forecast" to its huge collection of research reports.

After 30 years of development, the China's diagnostic reagent industry achieved a market size of nearly RMB 20 billion in 2014, a YoY growth of 15.7%. Currently nearly 90% downstream users of China's diagnostic reagent market comes from hospitals. 

There's still a huge growth potential in China's diagnostic reagent industry. China accounts for 20% of total population worldwide, but only take up 7% of global diagnostic reagent market in 2014. The average diagnostic reagent expense in China is only around $3, far below the average of $28 in the developed countries.

Currently there are about 300 diagnostic reagent enterprises in China and the industry concentration is still low. Large companies in China include: KHB, Da An Gene, Maker, HTA etc. Foreign brands accounts for over 50% of China's diagnostic reagent market in 2014, especially in high-end fields. The market share of domestic enterprises mainly comes from biochemical reagents.


China has fulfilled the import substitution of biochemical reagents, intensified competition has largely squeezed the profits in this subfield. Chemiluminescence Immunoassay (CLIA) and molecular diagnosis will be the most promising subfields in China's diagnostic reagent industry.

New Industries Biomedical Engineering Co., Ltd is the leading CLIA enterprise in China. Currently the company owns 102 chemiluminescent reagents and 8 models of CLIA analyzer. The company achieved reagents sales of RMB 331 million and reagents products has exported to Swiss, France, and Italy etc.


Zeesan Biotech is the leading molecular diagnosis enterprise in China. The company achieved molecular diagnosis reagents sales of RMB 11.85 million in 2014. Zeesan's products covers infectious disease (mainly phthisis), tumor (mainly leukemia) and genetic disease.


Related Reports:-

China Diagnostic Reagent Industry Report, 2013-2016

Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013. Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.

Global Molecular Diagnostics Market Report: 2014 Edition

Over the years, medical science has made unprecedented progress in almost every sphere of human anatomy. In the pursuit, pathological sciences, in particular, have brought forth advancements that rendered the possibility of deploying certain tests that are performed on patient samples, including blood and tissues, in order to detect the presence of concerning physiological/pathological state, or concerning congenital abnormality. Essentially, In-vitro Diagnostics (IVD) have earned the title of ‘silent champion’ of the healthcare industry since this segment influences more than half of the decision-making in the overall healthcare industry.


About Us:

ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact: 
Mr. Nachiket
Tel:+1-518-618-1030 
Toll Free: 866-997-4948
Labels: , ,

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)